Key facts
- Andrew Steele, an Olympic medallist, has raised nearly £5 million for his health tech venture, Stride.
- Stride offers multiomic testing, integrating genomics, microbiome, and protein profile diagnostics.
- The company aims to provide a holistic view of an individual's biology through an engaging digital dashboard.
- Stride also develops tailored supplements based on test results.
- Steele previously co-founded DNAfit, which was acquired by Prenetics, and was part of the team that led Prenetics to a NASDAQ IPO.
Andrew Steele, a former Olympic runner for Great Britain, has secured nearly £5 million in funding for his health technology company, Stride. The venture aims to make personalized health and wellness accessible by integrating various diagnostic tests into a single, user-friendly digital platform.
Stride offers multiomic testing, which includes genomics, microbiome analysis, and blood profiling, with plans to incorporate biological age and oral health tests in the future. The company's vision is to provide individuals with a holistic understanding of their internal biology, moving beyond fragmented point solutions. Based on these comprehensive results, Stride also develops tailored supplements.
Steele's journey into health tech began after his athletic career. He was approached by a genetic scientist seeking feedback on a genetic test for athletic performance, which led him to co-found DNAfit in 2013. DNAfit was acquired by Prenetics in 2018, and Steele played a role in the company's subsequent NASDAQ IPO in 2022. He then founded Stride in 2023, building on his experience in personalized health and diagnostics. Stride has recently expanded its reach in North America through a partnership with Unity Fitness Canada.